ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,732,075 | +34.4% | 100,666 | +52.3% | 0.05% | +63.3% |
| Q2 2023 | $2,032,129 | +76295.8% | 66,107 | -10.5% | 0.03% | -34.8% |
| Q1 2023 | $2,660 | -13.3% | 73,832 | -4.9% | 0.05% | -24.6% |
| Q4 2022 | $3,068 | -99.9% | 77,642 | -6.6% | 0.06% | -20.8% |
| Q3 2022 | $3,341,000 | -11.3% | 83,163 | -7.2% | 0.08% | -7.2% |
| Q2 2022 | $3,767,000 | -19.0% | 89,598 | -24.9% | 0.08% | -6.7% |
| Q1 2022 | $4,648,000 | +59.3% | 119,299 | +104.6% | 0.09% | +29.0% |
| Q4 2021 | $2,918,000 | -37.9% | 58,305 | -55.1% | 0.07% | -25.8% |
| Q3 2021 | $4,698,000 | +18.3% | 129,997 | +34.2% | 0.09% | +19.2% |
| Q2 2021 | $3,970,000 | +55.6% | 96,857 | +65.6% | 0.08% | +30.0% |
| Q1 2021 | $2,551,000 | -12.4% | 58,493 | +0.5% | 0.06% | -15.5% |
| Q4 2020 | $2,912,000 | +187.5% | 58,180 | +141.6% | 0.07% | +153.6% |
| Q3 2020 | $1,013,000 | – | 24,085 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |